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Edited by Beat ImhofAbstract Lactoferrin (LF) is a multifunctional iron-binding
glycoprotein, which plays a variety of biological processes
including immunity. In this study, we demonstrate that human
LF upregulates KDR/Flk-1 mRNA and protein levels in
HUVECs at an optimal concentration of 5 lg/ml, which subse-
quently promotes the VEGF-induced proliferation and migration
of the endothelial cells. Exposure of HUVECs to LF signiﬁ-
cantly increased VEGF-induced ERK MAP kinase phosphoryla-
tion. The maximal stimulation of KDR/Flk-1 expression by LF
was correlated with LF-induced increase in cell proliferation
and migration. These ﬁndings suggest that LF may stimulate
in vivo angiogenesis via upregulation of KDR/Flk-1 expression
in endothelial cells.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Proliferation1. Introduction
Lactoferrin (LF) is an iron-binding glycoprotein belonging
to the transferrin family. LF is present in breast milk, epithelial
secretions, and the secondary granules of neutrophilic leuko-
cytes [1,2]. Serum LF levels are derived primarily from neutro-
phils and in healthy adults LF circulates at concentrations of
2–7 lg/ml, but its local concentrations tend to be far higher
during inﬂammation [3]. A number of biological roles are as-
cribed to LF, including host defenses against microbial infec-
tion, bone formation, modulation of the inﬂammatory
response, and angiogenesis [1–7].
Angiogenesis performs essential functions in a variety of
physiological and pathological processes such as wound heal-
ing, tumor growth, metastasis and hypoxia [8,9]. Among
numerous proangiogenic mediators [10–13], VEGF-A is best
characterized as a VEGF family member which is an endothe-
lial cell speciﬁc mitogen and induces angiogenesis [14]. VEGFAbbreviations: VEGF, vascular endothelial growth factor; KDR/Flk-1,
kinase insert domain-containing receptor/fms-like tyrosine kinase 1;
Flt-1, fetal liver kinase-1; ERK, extracellular signal regulated kinase;
MAPK, mitogen activated protein kinase; PMA, phorbol-12-myristate
13-acetate
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cently, human and bovine LF were shown to modulate
VEGF-A-mediated angiogenesis in vivo [5–7]. However, the
molecular mechanism underlying this process has yet to be elu-
cidated. In this study, we showed that human LF potentiates
VEGF-induced endothelial cell migration and proliferation
via the upregulation of KDR/Flk-1 expression in endothelial
cells.2. Materials and methods
2.1. Reverse transcription and real time polymerase chain reaction
Total RNA was isolated from HUVECs by using RNA-Bee isola-
tion kit (Tel-Test Inc.). The following primers were used in this study:
KDR/Flk-1, 5 0-CGACCTTGGTTGTGGCTGACT-3 0 and 5 0- CCC-
TTCTGGTTGGTGGCTTTG-3 0; Flt-1, 5 0-AACAAAGTCGGGA-
GAGGA-3 0 and 5 0-TGACAAGAAGTAGCCAGAAGA-3 0; b-actin,
5 0-ATCTGGCACCACACCTTCTA-3 0 and 5 0-CGTCATACTCCTG-
CTTGCTG-30. Real time PCRs were performed using the real-time
ﬂuorescence detection method using the LightCycler System with a
First-Start DNA Master SYBR Green I kit (Roche Diagnostics).
The primer sequences for KDR/Flk-1 were as follows: 5 0-TCTCAA-
TGTGGTCAACCTTQCTAGG-3 0; 5 0- TTAAACGTCTTAAGGGT-
GTTAGTGG-3 0. The primer sequences for Flt-1 were as follows:
5 0-CGACGTGTGGTCTTACGGAGTA-30; 5 0-CTTCCCTCAGGC-
GACTGC-30. The cycling conditions were as follows: initial denatur-
ation at 95 C for 10 min, followed by 40 ampliﬁcation cycles of
95 C for 15 s, 56 C for 5 s and 72 C for 15 s. After ampliﬁcation,
the temperature was slowly elevated above the melting temperature
of the PCR product to measure the ﬂuorescence and thereby to deter-
mine the melting curve. A negative control without cDNA template
was performed to assess the overall speciﬁcity.2.2. Cell based ELISA
For enzyme-linked immunosorbent assay (ELISA), ﬂat-bottom 96-
well plates were coated with 0.1% gelatin. HUVECs were cultured in
96-well plate (2 · 104 cells/well) for 24 h. Cells were washed with PBS
and ﬁxed with 3.7% formaldehyde in PBS for 15 min. After blocking
with 3% BSA/PBS, cells were incubated with 0.2 mg/ml of anti-
KDR/Flk-1 monoclonal antibody in 1% BSA/PBS for 1 h at room
temperature and washed three times with PBS. After 1 h incubation
with a 1:5000 dilution of peroxidase-labeled goat anti-mouse IgG in
1% BSA in PBS, wells were washed three times 0.5% Tween 20 in
PBS. The bound peroxidase was detected using the chemiluminescense
ELISA reagent.2.3. Western blot analysis
Western blot analysis was performed as described previously [18].
Antibodies against KDR/Flk-1, Flt-1 (Research Santa Cruz, Santa
Cruz, CA), and ERK1/2 (Cell Signaling Technology, Beverly, MA)
were utilized as primary antibodies and peroxidase-conjugated anti-
body was used as a secondary antibody.blished by Elsevier B.V. All rights reserved.
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HUVECs were grown with or without LF on chamber slides (Nalge
Nunc, IL). Cells were ﬁxed with 4% paraformaldehyde, washed in
PBS, and incubated overnight with polyclonal anti-KDR/Flk-1 anti-
body. Cells were then washed and incubated for 1 h with FITC-conju-
gated anti-rabbit antibodies. Fluorescence image analyses were
performed by using confocal microscope (Carl Zeiss, Germany).
2.5. Cell proliferation assay
The assay was conducted by using BrdU and a Detection Kit
(Roche, Indianapolis, IN). In brief, HUVECs were seeded in 0.1% gel-
atin-coated 96-well plates. After 12 h of LF treatment, VEGF (10 ng/
ml) was added. The BrdU-integrated DNA was quantitated by the rel-
ative luminescence unit (RLU) of each well using a Wallace Victor2
1420 Multilabel counter (Perkin–Elmer, Norwalk, CT).
2.6. Endothelial cell migration and scratch wound assays
Cell migration assay [19] and scratch wound assays [13] were con-
ducted as previously described. In brief, the lower chamber of a Boy-
den chamber (Neuro Probe Inc., Cabin John, MD) was loaded with
cells, and the membrane was laid over the cells. The upper chamber
was loaded with or without VEGF containing 0.1% BSA/M199. The
chamber was inverted and incubated for 3 h at 37 C and the migrated
cells were counted.
Scratch wounds were generated in conﬂuent HUVEC cultures with a
sterile 200-ll pipette tip. Cells were treated with LF (Sigma–Aldrich,
St. Louis, MO) for 12 h prior to VEGF (10 ng/ml) treatment. After
24 h, HUVECs were stained with Diﬀ-Quick (Baxter Healthcare
Corp., McGraw Park, IL) and photographed.
2.7. Chick chorioallantoic membrane assay
Modiﬁed chick CAM assays were performed as previously described
[18]. In brief, test samples in rat tail type I collagen (Collaborative Bio-
medical Products) were applied onto Thermonox disks (Nalge Nunc,
IL). The disks were loaded onto the CAM of 10-day-old embryos.
After 72 h of incubation, the areas around the loaded disks were pho-
tographed with a Nikon digital camera and the newly formed vessels
were counted. Each assay was conducted twice, and each experiment
contained 15 eggs per sample.Fig. 1. Human LF upregulates mRNA expression of KDR/Flk-1 in
HUVECs. (A) HUVECs were treated with various concentrations of
LF for 12 h. RT-PCR was performed with the same samples using
primer sets as described in Section 2. LF increased KDR/Flk-1 mRNA
levels but not Flt-1 levels. (B) HUVECs were treated with 5 lg/ml of
LF for the indicated times. LF increased KDR/Flk-1 mRNA after 12 h
of treatment. (C) Real-time quantitative RT-PCR of KDR/Flk-1 and
Flt-1 expression. The data are mean values ± S.D. from triplicates and
are representative of at least four experiments. *, P < 0.01 versus
vehicle.2.8. Statistical analysis
The data are presented as means ± S.D. and statistical comparisons
between groups were performed using 1-way ANOVA followed by
Student’s t test.3. Results and discussion
3.1. Human LF upregulates mRNA and protein expression of
KDR/Flk-1 in HUVECs
It was previously reported that the human iron-unsaturated
form of LF enhanced VEGF-A-mediated angiogenesis in vivoFig. 2. Human LF upregulates protein expression of KDR/Flk-1 in
HUVECs. HUVECs were treated with various concentrations of LF
for 12 h. (A) Cell based ELISA showed that KDR/Flk-1 protein levels
were increased in LF-treated HUVECs, but Flt-1 protein levels were
not changed. *, P < 0.01 versus vehicle. PMA (100 nM): Phorbol-12-
myristate 13-acetate, RLU: relative luminescence unit. The data are
mean values ± S.D. from quadruplicates and are representative of at
least three experiments. (B) Western blot analysis showed that LF
increased KDR/Flk-1 protein levels in HUVECs. Molecular size
markers are indicated on the left. (C) KDR/Flk-1 protein levels were
increased in HUVECs treated with LF in immunoﬂuorescent staining
of cells with anti-KDR/Flk-1 antibodies. The photo ﬁgures in the left
panels are immunoﬂuorescence-stained cells, and those in the right
panels are photomicrographs. Magniﬁcation: ·800.
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fects of LF on VEGF-A-mediated angiogenesis, we ﬁrst
investigated the possibility that the LF might increase VEGF
receptor expression, which would potentiate VEGF action, as
it was known that LF is internalized, and translocated into
the nucleus, where it regulates gene expression [20–23]. We
performed RT-PCR and real time PCR analysis to evaluate
the mRNA levels for the KDR/Flk-1 and Flt-1 VEGF recep-
tors. As shown in Fig. 1A and C, LF stimulated KDR/Flk-1
mRNA expression at maximal levels of approximately 5 lg/
ml, but did not aﬀect Flt-1 expression. LF-induced stimula-
tion of KDR/Flk-1 mRNA expression was maximal at
approximately 12 h of treatment (Fig. 1B). We next measured
KDR/Flk-1 protein levels by Western blot analysis and cell
based ELISA, determining that LF increased KDR/Flk-1
protein levels with maximal levels at 5 lg/ml (Fig. 2A and
B). KDR/Flk-1 proteins were also detected in endothelial
cells by confocal microscopic analysis of immunoﬂuores-
cent-stained cells. As expected, the ﬂuorescence intensity of
KDR/Flk-1 expression increased in LF-treated HUVECs
compared with the controls (Fig. 2C). The increase in
KDR/Flk-1 protein levels coincided with that of the mRNA
levels. These ﬁndings suggested that LF upregulates the
expression of the KDR/Flk-1 gene, which in turn enhances
the action of VEGF in HUVECs.Fig. 3. Human LF stimulates endothelial cell proliferation and
phosphorylation of MAPK mediated by VEGF-A. (A) HUVECs
were pretreated with various concentrations of LF for 12 h and then
treated with or without VEGF (10 ng/ml). HUVECs proliferation at
diﬀerent LF concentrations was compared with that observed in the
presence of VEGF alone. *, P < 0.01 versus VEGF alone; **, P < 0.01
versus vehicle. RLU: relative luminescence unit. The data are mean
values ± S.D. from quadruplicates and are representative of at least
three experiments. (B) HUVECs were pretreated with various concen-
trations of LF for 12 h and then treated with or without VEGF (10 ng/
ml). Pretreatment of HUVECs with LF increased the VEGF-induced
phosphorylation of ERK1/2 in a dose-dependent manner. (C)
HUVECs were pretreated with 5 lg/ml of LF for the indicated times
and then treated with VEGF. The VEGF-induced phosphorylation of
ERK1/2 was increased in HUVECs after 12 h of LF pretreatment.3.2. Human LF stimulates endothelial cell proliferation and
phosphorylation of MAPK
Mitogenic activity of endothelial cells can be stimulated by a
variety of growth factors including VEGF [10–12]. We tested
the mitogenic eﬀect of LF on HUVECs and observed that
LF alone did not promote endothelial cell growth signiﬁcantly.
However, when HUVECs were pretreated with LF at various
concentrations for 12 h and subsequently exposed to VEGF,
LF stimulated VEGF-induced cell proliferation further. Cell
proliferation increased approximately 3-fold over VEGF alone
at 5 lg/ml of LF (Fig. 3A), which was also correlated with the
LF-induced increase in the KDR/Flk-1 mRNA and protein
levels.
KDR/Flk-1 transduces the VEGF signal via MAPK activa-
tion [19,24,25]. VEGF induced ERK1/2 phosphorylation,
which increased markedly when cells were pretreated with
LF (Fig. 3B). It is noteworthy that ERK1/2 phosphorylation
was increased after 12 h (Fig. 3C), which coincided with an in-
crease in KDR/Flk-1 protein levels. The results indicate that
the cell proliferation induced by VEGF and LF was associated
with the sensitization of the MAPK pathway in the HUVECs.
3.3. Human LF stimulates endothelial cell migration and
angiogenesis in vivo
We ﬁrst investigated the eﬀects of LF on HUVEC migration
using Boyden chamber assays. As shown in Fig. 4A, LF stim-
ulated HUVEC migration in the presence of VEGF-A, but did
not induce endothelial cell migration by itself. We observedFig. 4. Human LF stimulates endothelial cell migration mediated by
VEGF-A. (A) HUVECs were pretreated with various concentrations
of LF for 12 h and then treated with or without VEGF (10 ng/ml).
Human LF signiﬁcantly stimulated the VEGF-mediated migration of
HUVECs over the presence of VEGF alone. *, P < 0.01 versus VEGF
alone; **, P < 0.01 versus vehicle. The data are mean values ± S.D.
from quadruplicates and are representative of at least three experi-
ments. (B) HUVECs were pretreated with various concentrations of
LF for 12 h and then treated with or without VEGF (10 ng/ml). LF
enhanced endothelial cell migration in scratch wound healing assay.
((a) medium alone; (b) VEGF alone; (c–f), LF 2.5, 5, 10, 20 lg/ml in
the presence of 10 ng/ml VEGF). Magniﬁcation: ·20.
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tion, even in the presence of VEGF-A (data not shown), which
was consistent with the previous report that human iron-unsat-
urated form of LF but not the iron-loaded forms of LF en-
hanced VEGF-A-mediated angiogenesis in vivo [6]. The
enhancement of VEGF-mediated endothelial cell migration
by LF was also demonstrated by scratch wound assays
(Fig. 4B). The stimulatory activity of LF was maximal at a
concentration of approximately 5 lg/ml.
We conﬁrmed that LF promoted VEGF-mediated angiogen-
esis in vivo by CAM assays [6]. LF clearly enhanced angiogen-
esis in vivo in the presence of VEGF with no visible eﬀects on
the pre-existing blood vessels, compared with that of VEGF
alone (Fig. 5A). Quantitative analysis revealed that LF in-
creased the number of newly-formed blood vessels as com-
pared with that of VEGF alone, in a dose-dependent manner
(Fig. 5B).
Recent papers indicate that apo-bovine LF inhibits VEGF-
mediated angiogenesis [5,7], which is contrast to the stimula-
tory eﬀects of apo-human LF in vivo [6]. It has been suggested
that human LF and bovine LF play speciﬁc but contrary roles
in angiogenesis. The diﬀerence in modulating angiogenesis be-
tween human and bovine LF still remains controversial. In this
report, we demonstrated that human LF upregulates KDR/
Flk-1 mRNA expression and protein levels, and subsequentlyFig. 5. Human LF stimulates angiogenesis mediated by VEGF-A
in vivo. (A) LF or LF with VEGF was loaded on the CAMs of day 10
chick embryos. After 72 h incubation, eggs were processed as described
in Section 2. Photographs of vehicle, VEGF, and diﬀerent LF
concentration in the presence of VEGF. ((a) Vehicle; (b) VEGF alone;
(c–f), LF 0.1, 1, 10, 100 lg/egg in the presence of VEGF 100 ng/egg).
(B) Quantiﬁcation of newly formed blood vessels in the presence of
diﬀerent LF concentrations was compared with that observed in the
presence of either medium or VEGF alone. *, P < 0.01 versus VEGF
alone; **, P < 0.01 versus vehicle. The data are mean values ± S.D.
from 15 eggs and are representative of at least two experiments.stimulates VEGF-mediated endothelial cell migration and pro-
liferation. Our results may provide some explanation for previ-
ously observed eﬀect of subcutaneously infused apo-human
LF which signiﬁcantly enhanced VEGF-mediated angiogenesis
in vivo [6]. The indirect eﬀects of human LF in angiogenesis
may perform functions in processes including bone formation
and neonatal development. Our ﬁndings could further serve to
understand the mechanisms underlying LF’s eﬀects on VEGF-
mediated angiogenesis, and to raise the possibility of potential
uses for LF in the prevention and treatment of diseases includ-
ing ischemic diseases and hypoxia.
Acknowledgement: This work was supported by Grant No. R01-2004-
000-10481-0 from the Basic Research Program of the Korea Science &
Engineering Foundation.References
[1] Farnaud, S. and Evans, R.W. (2003) Lactoferrin-a multifunc-
tional protein with antimicrobial properties. Mol. Immunol. 40,
395–405.
[2] Ward, P.P., Uribe-Luna, S. and Conneely, O.M. (2002) Lacto-
ferrin and host defense. Biochem. Cell Biol. 80, 95–102.
[3] Caccavo, D., Sebastiani, G.D., Di Monaco, C., Guido, F.,
Galeazzi, M., Ferri, G.M., Bonomo, L. and Afeltra, A. (1999)
Increased levels of lactoferrin in synovial ﬂuid but not in serum
from patients with rheumatoid arthritis. Int. J. Clin. Lab. Res. 29,
30–35.
[4] Cornish, J., Callon, K.E., Naot, D., Palmano, K.P., Banovic, T.,
Bava, U., Watson, M., Lin, J.M., Tong, P.C., Chen, Q., Chan,
V.A., Reid, H.E., Fazzalari, N., Baker, H.M., Baker, E.N.,
Haggarty, N.W., Grey, A.B. and Reid, I.R. (2004) Lactoferrin is a
potent regulator of bone cell activity and increases bone forma-
tion in vivo. Endocrinology 145, 4366–4374.
[5] Norrby, K., Mattsby-Baltzer, I., Innocenti, M. and Tuneberg, S.
(2001) Orally administered bovine lactoferrin systemically inhibits
VEGF(165)-mediated angiogenesis in the rat. Int. J. Cancer 91,
236–240.
[6] Norrby, K. (2004) Human apo-lactoferrin enhances angiogenesis
mediated by vascular endothelial growth factor A in vivo. J. Vasc.
Res. 41, 293–304.
[7] Shimamura, M., Yamamoto, Y., Ashino, H., Oikawa, T., Hazato,
T., Tsuda, H. and Iigo, M. (2004) Bovine lactoferrin inhibits
tumor-induced angiogenesis. Int. J. Cancer 111, 111–116.
[8] Folkman, J. (1995) Angiogenesis in cancer, vascular, rheumatoid
and other disease. Nat. Med. 1, 27–31.
[9] Isner, J.M. and Asahara, T. (1999) Angiogenesis and vasculo-
genesis as therapeutic strategies for postnatal neovascularization.
J. Clin. Invest. 103, 1231–1236.
[10] Lobb, R., Sasse, J., Sullivan, R., Shing, Y., D’Amore, P., Jacobs,
J. and Klagsbrun, M. (1986) Puriﬁcation and characterization of
heparin-binding endothelial cell growth factors. J. Biol. Chem.
261, 1924–1928.
[11] Fett, J.W., Strydom, D.J., Lobb, R.R., Alderman, E.M., Bethune,
J.L., Riordan, J.F. and Vallee, B.L. (1985) Isolation and
characterization of angiogenin, an angiogenic protein from
human carcinoma cells. Biochemistry 24, 5480–5486.
[12] Senger, D.R., Galli, S.J., Dvorak, A.M., Perruzzi, C.A., Harvey,
V.S. and Dvorak, H.F. (1983) Tumor cells secrete a vascular
permeability factor that promotes accumulation of ascites ﬂuid.
Science 219, 983–985.
[13] Huang, M.T., Mason, J.C., Birdsey, G.M., Amsellem, V.,
Gerwin, N., Haskard, D.O., Ridley, A.J. and Randi, A.M.
(2005) Endothelial intercellular adhesion molecule (ICAM)-2
regulates angiogenesis. Blood 106, 1636–1643.
[14] Leung, D.W., Cachianes, G., Kuang, W.J., Goeddel, D.V. and
Ferrara, N. (1989) Vascular endothelial growth factor is a secreted
angiogenic mitogen. Science 246, 1306–1309.
[15] Parikh, A.A. and Ellis, L.M. (2004) The vascular endothelial
growth factor family and its receptors. Hematol. Oncol. Clin. N.
Am. 18, 951–971.
4336 C.W. Kim et al. / FEBS Letters 580 (2006) 4332–4336[16] Shibuya, M., Yamaguchi, S., Yamane, A., Ikeda, T., Tojo, A.,
Matsushime, H. and Sato, M. (1990) Nucleotide sequence and
expression of a novel human receptor-type tyrosine kinase gene
(ﬂt) closely related to the fms family. Oncogene 5, 519–524.
[17] Terman, B.I., Carrion, M.E., Kovacs, E., Rasmussen, B.A., Eddy,
R.L. and Shows, T.B. (1991) Identiﬁcation of a new endothelial
cell growth factor receptor tyrosine kinase. Oncogene 6, 1677–
1683.
[18] Jia, H., Bagherzadeh, A., Bicknell, R., Duchen, M.R., Liu, D. and
Zachary, I. (2004) Vascular endothelial growth factor (VEGF)-D
and VEGF-A diﬀerentially regulate KDR-mediated signaling and
biological function in vascular endothelial cells. J. Biol. Chem.
279, 36148–36157.
[19] Hwang, J., Kim, C.W., Son, K.N., Han, K.Y., Lee, K.H.,
Kleinman, H.K., Ko, J., Na, D.S., Kwon, B.S., Gho, Y.S. and
Kim, J. (2004) Angiogenic activity of human CC chemokine
CCL15 in vitro and in vivo. FEBS Lett. 570, 47–51.
[20] Garre, C., Bianchi-Scarra, G., Sirito, M., Musso, M. and
Ravazzolo, R. (1992) Lactoferrin binding sites and nuclear
localization in K562(S) cells. J. Cell. Physiol. 153, 477–482.[21] He, J. and Furmanski, P. (1995) Sequence speciﬁcity and
transcriptional activation in the binding of lactoferrin to DNA.
Nature 373, 721–724.
[22] Penco, S., Pastorino, S., Bianchi-Scarra, G. and Garre, C.
(1995) Lactoferrin down-modulates the activity of the
granulocyte macrophage colony-stimulating factor promoter
in interleukin-1 beta-stimulated cells. J. Biol. Chem. 270,
12263–12268.
[23] Son, K.N., Park, J., Chung, C.K., Chung, D.K., Yu, D.Y., Lee,
K.K. and Kim, J. (2002) Human lactoferrin activates transcrip-
tion of IL-1beta gene in mammalian cells. Biochem. Biophys. Res.
Commun. 290, 236–241.
[24] Gille, H., Kowalski, J., Li, B., LeCouter, J., Moﬀat, B.,
Zioncheck, T.F., Pelletier, N. and Ferrara, N. (2001) Analysis
of biological eﬀects and signaling properties of Flt-1
(VEGFR-1) and KDR (VEGFR-2). J. Biol. Chem. 276,
3222–3230.
[25] Suhardja, A. and Hoﬀman, H. (2003) Role of growth factors and
their receptors in proliferation of microvascular endothelial cells.
Microsc. Res. Techniq. 60, 70–75.
